Clinical trial
Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity
NCT00367783 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00367783 |
|---|---|
| Title | Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity |
| Official title | A 12-Week, Phase 2A, Randomized, Subject And Investigator Blind, Placebo-Controlled Trial To Evaluate The Effect Of CP-741,952 On Weight Loss In Otherwise Healthy Overweight And Obese Adult Subjects |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Obesity |
| Intervention type | Drug |
| Interventions | CP-741, 952 |
| Enrollment | 100 |
| Start date | Jun 1, 2006 |
| Completion | Apr 1, 2007 |
| First posted | Aug 23, 2006 |
| Last update posted | Aug 1, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: